Osteitis deformans, also known as Paget’s disease of bone, presents a complex therapeutic challenge. Understanding the synergy between cytarabine and daunorubicin for injection might unveil new treatment avenues. Current research primarily focuses on their use in oncology, yet their potential in managing bone-related disorders sparks interest. A deep dive into this synergy and its impact
